Cempra Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 01, 2016 17:05 ET
|
Melinta Therapeutics, Inc.
NDA submissions completed for solithromycin intravenous and oral capsule formulations in the treatment of community-acquired pneumonia Management to host webcast and conference call tomorrow at...
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
May 01, 2016 17:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP ...
Cempra to Report First Quarter 2016 Financial Results
April 25, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9
March 08, 2016 16:10 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
March 07, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...
Cempra to Present at the Cowen and Company 36th Annual Healthcare Conference
February 29, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Fourth Quarter and Full Year 2015 Financial Results
February 17, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic...
Cempra to Present Solithromycin Data at ID Week 2015
October 05, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
September 24, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Three Upcoming Investor Conferences
September 03, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...